Literature DB >> 24510016

Petaloid-pattern pigmentary retinopathy: a novel case report.

Tapas Ranjan Padhi1, Subhadra Jalali, Krushna Gopal Panda, Sujoy Mukherjee, Neha Mohan, Pushpalata Agroiya, Taraprasad Das.   

Abstract

We report the case of a 6-year-old girl with an unusual petaloid-pattern pigmentary retinopathy associated with nyctalopia and reduction of vision which had been invariably static over the past 5 years. We performed a comprehensive ophthalmic examination including fundoscopy, autofluorescent imaging, electroretinography and optical coherence tomography. There were diffuse retinal pigment epithelium (RPE) washout areas with blotches of pigment distributed in the pattern of a petal with marked chorioretinal atrophy and scar at the fovea. The arterial caliber was normal. Investigations ruled out intrauterine and neonatal infection. Systemically, she was healthy with normal intellect but with 3-month delayed milestones of development. She had used valproic acid for seizure disorder (without any organic central nervous system lesion) from 2-5 years of age. Electroretinography showed extinguished scotopic responses with slight reduction in cone responses. Optical coherence tomography showed a scar with attenuated RPE-choriocapillary complex at the macula. Her clinical profile did not fully match with any previously described pigmentary retinopathies except rod-cone dystrophy and choroidal dystrophy to a certain extent. The pigmentary retinopathy reported here is a combination of a petaloid pattern of pigmentary disturbance, stationary reduction of vision, nyctalopia, normal intellect and marginal delayed milestones. In the absence of such a description in the literature we named this disorder as petaloid-pattern pigmentary retinopathy.

Entities:  

Mesh:

Year:  2014        PMID: 24510016     DOI: 10.1007/s10792-014-9909-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  11 in total

1.  Ocular manifestations of incontinentia pigmenti.

Authors:  G Holmström; K Thorén
Journal:  Acta Ophthalmol Scand       Date:  2000-06

2.  FURTHER STUDIES CONCERNING THE ACCUMULATION OF POLYCYCLIC COMPOUNDS ON UVEAL MELANIN.

Authors:  A M POTTS
Journal:  Invest Ophthalmol       Date:  1964-08

3.  Therapeutic potential of valproic acid for retinitis pigmentosa.

Authors:  C M Clemson; R Tzekov; M Krebs; J M Checchi; C Bigelow; S Kaushal
Journal:  Br J Ophthalmol       Date:  2010-07-20       Impact factor: 4.638

4.  Clinical manifestations of postnatal and congenital rubella.

Authors:  L Z Cooper; S Krugman
Journal:  Arch Ophthalmol       Date:  1967-04

5.  The ocular manifestations of congenital rubella.

Authors:  S M Wolff
Journal:  Trans Am Ophthalmol Soc       Date:  1972

6.  Chloroquine retinopathy. Investigation of discrepancy between dark adaptation and electroretinographic findings in advanced stages.

Authors:  A E Krill; A M Potts; C E Johanson
Journal:  Am J Ophthalmol       Date:  1971-02       Impact factor: 5.258

7.  Gyrate atrophy of the choroid and retina. Long-term reduction of ornithine slows retinal degeneration.

Authors:  M I Kaiser-Kupfer; R C Caruso; D Valle
Journal:  Arch Ophthalmol       Date:  1991-11

8.  Phenotypic variation in enhanced S-cone syndrome.

Authors:  Isabelle Audo; Michel Michaelides; Anthony G Robson; Marko Hawlina; Veronika Vaclavik; Jennifer M Sandbach; Magella M Neveu; Chris R Hogg; David M Hunt; Anthony T Moore; Alan C Bird; Andrew R Webster; Graham E Holder
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

9.  Diagnostic clinical findings of a new syndrome with night blindness, maculopathy, and enhanced S cone sensitivity.

Authors:  M F Marmor; S G Jacobson; M H Foerster; U Kellner; R G Weleber
Journal:  Am J Ophthalmol       Date:  1990-08-15       Impact factor: 5.258

Review 10.  Retinopathy induced by drugs and herbal medicines.

Authors:  C Nencini; L Barberi; F M Runci; L Micheli
Journal:  Eur Rev Med Pharmacol Sci       Date:  2008 Sep-Oct       Impact factor: 3.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.